351 related articles for article (PubMed ID: 36193978)
1. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy
Mei H; Guo Y; Zhao JT; Yang J; Sun WJ; Zhang DK; He P; Shi G; Su NY; Han R; Lan CH
Therap Adv Gastroenterol; 2022; 15():17562848221142925. PubMed ID: 36600686
[TBL] [Abstract][Full Text] [Related]
3. High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Yun JW; Wang C; Yu Y; Xu HM; Gou LZ; Li XL; Yi GR; Lin YM; Han TY; Zhang DK
Br J Clin Pharmacol; 2023 Jan; 89(1):232-241. PubMed ID: 35947524
[TBL] [Abstract][Full Text] [Related]
4. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
5. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
[TBL] [Abstract][Full Text] [Related]
6. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
7. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
8. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
Zhang C; Zhang J; Cheng YJ
Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
[TBL] [Abstract][Full Text] [Related]
9. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
Chen L; He J; Wang L; Ge Q; Chu H; Chen Y; Chen X; Long Y; Deng Y; He H; Li A; Chen S
Clin Exp Med; 2018 Nov; 18(4):569-576. PubMed ID: 29876770
[TBL] [Abstract][Full Text] [Related]
10. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
[TBL] [Abstract][Full Text] [Related]
11. High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis.
Wang H; Kong QZ; Li YY; Yang XY; Zuo XL
J Dig Dis; 2024 Mar; 25(3):163-175. PubMed ID: 38577962
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
13. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
[TBL] [Abstract][Full Text] [Related]
14. Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Xie Y; Hu Y; Zhu Y; Wang H; Wang QZ; Li YQ; Wang JB; Zhang ZY; Zhang DK; Liu XW; Lu NH
Helicobacter; 2023 Jun; 28(3):e12978. PubMed ID: 37002653
[TBL] [Abstract][Full Text] [Related]
15. A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Zhang J; Han C; Lu WQ; Wang N; Wu SR; Wang YX; Ma JP; Wang JH; Hao C; Yuan DH; Liu N; Shi YQ
J Dig Dis; 2020 May; 21(5):256-263. PubMed ID: 32348007
[TBL] [Abstract][Full Text] [Related]
16. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
17. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
Wang J; Cao Y; He W; Li X
Medicine (Baltimore); 2021 Dec; 100(51):e28323. PubMed ID: 34941132
[TBL] [Abstract][Full Text] [Related]
19. High-dose dual therapy
Zhao Z; Zou PY; Su NY; Guo Y; Wang XW; Zhao JT; Mei H; Shi Q; Wang B; Chen DF; Lan CH
Therap Adv Gastroenterol; 2022; 15():17562848221145566. PubMed ID: 36600682
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
